CENTOGENE raises Euro 25 million

14-Jun-2017 - Germany

CENTOGENE AG, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deutsche Private Equity, Careventures and CIC Capital. The proceeds of the financing will be used to accelerate the company’s further growth and expansion plans in the business segments of worldwide Genetic Testing, Pharmaceutical Collaborations and Big Data-Solutions.

CENTOGENE AG already commands the largest test portfolio for rare genetic diagnostics in the world having analyzed patients from over 110 countries, allowing CENTOGENE to generate unique and global insights into the epidemiological basis of hereditary disorders and the link between genotypic and phenotypic data. “There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases.

This creates a tremendous market opportunity for us”, comments Prof. Arndt Rolfs, MD, CEO and Founder of CENTOGENE AG. “We are very pleased to have this international investor consortium on board who not only shares our vision for future growth to put innovation into precision medicine, but also provides the necessary access to an international network to realize our vision on a real global basis.”

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy